WHO: COVID-19 might spread in air of closed spaces | US records more than 60,500 new COVID-19 cases in one day | Gilead starts trial of inhalable remdesivir
July 10, 2020
AABB SmartBrief
News for the transfusion medicine and cellular therapy communitySIGN UP ⋅   SHARE
Top Story
The World Health Organization issued a scientific brief Thursday saying the possibility that the novel coronavirus is airborne cannot be ruled out, and acknowledging that it might be transmitted through aerosols or tiny air droplets in closed indoor spaces such as restaurants and gyms. The WHO said more research is needed, but respiratory droplets are still thought to be the primary route of transmission.
Full Story: CNBC (7/9),  The Hill (7/9) 
LinkedIn Twitter Facebook Email
The Easy Way to Comply with FDA Guidance
With the Platelet PGDprime® test, the average user can easily test daily platelet demand in < 1 hour. Test once per dose, only on the day of transfusion. It's the only FDA-cleared rapid test that extends the life of your leukoreduced apheresis platelet inventory to 7 days. Learn more.
ADVERTISEMENT:
Science & Health
The US reported more than 60,500 new cases of COVID-19 Thursday, the largest single-day spike seen in any country since the pandemic started, with 41 out of 50 states reporting rising infections over the past two weeks. National Institute of Allergy and Infectious Diseases Director Anthony Fauci urged hard-hit states such as California, Florida, Texas and Arizona -- which account for half of new cases -- to seriously consider halting their reopening process and analyze "what did not work well and try to mitigate that."
Full Story: Reuters (7/10),  The Hill (7/9) 
LinkedIn Twitter Facebook Email
Emerging Trends
Gilead Sciences has begun evaluating an inhalable form of remdesivir for COVID-19 treatment that could be used outside hospital settings, launching early-stage testing in nearly 60 healthy adults. The company also intends to test remdesivir in combination with anti-inflammatory drugs.
Full Story: Reuters (7/8) 
LinkedIn Twitter Facebook Email
Industry News & Practice
A collaboration between Gilead Sciences and Precision Biosciences to develop new hepatitis B virus therapies has been terminated. Precision will regain the license to its hepatitis B program.
Full Story: FierceBiotech (7/8) 
LinkedIn Twitter Facebook Email
Government & Regulatory
The FDA has granted orphan drug designation and priority review status to Astex Pharmaceuticals' Inqovi, or decitabine and cedazuridine, for treating individuals with myelodysplastic syndromes or chronic myelomonocytic leukemia, after a trial showed that Inqovi had a similar safety profile and drug concentration as intravenous decitabine.
Full Story: Medscape (free registration) (7/8) 
LinkedIn Twitter Facebook Email
The NIH announced the launch of a national clinical trials network, dubbed the COVID-19 Prevention Trials Network, to help perform late-stage clinical trials of COVID-19 vaccines and other treatments. A vaccine co-developed by Moderna and the National Institute of Allergy and Infectious Diseases is expected to be tested in the first late-stage trial conducted through COVPN this summer.
Full Story: Regulatory Focus (7/8) 
LinkedIn Twitter Facebook Email
The FDA has given emergency use authorization to Assure Tech for its Assure COVID-19 IgG/IgM Rapid Test Device, which can deliver results within 15 minutes, and to Laboratorio Clinico Toledo for its Laboratorio Clinico Toledo SARS-CoV-2 Assay.
Full Story: GenomeWeb Daily News (free registration) (7/8) 
LinkedIn Twitter Facebook Email
Association News
AABB will host an eCast, "The Transfusion Committee: How to be Effective and Sustaining," on Wednesday, July 22, at 2 p.m. Eastern Time. In this program, Jim Gorham, MD, PhD, medical director, Blood Bank and Transfusion Services, at the University of Virginia, and Carolyn Burns, MD, patient blood management physician advisor, will describe ways to increase the effectiveness and sustainability of transfusion committees in the current health care climate. Speakers will also describe methods to integrate clinical stakeholders into the facility's transfusion committee, engage members of the committee to fully participate in committee meetings and effectively utilize committee members to aid in realizing the committee's goals.
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
Sharing AABB SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy & share your personalized link:
smartbrief.com/aabb/?referrerId=eSriBJbAIQ
The mold of your life is in your hands to break.
J.R.R. Tolkien,
writer, poet, philologist, academic
LinkedIn Twitter Facebook Email
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004